Treatment group (n = 33) | Control group (n = 31) | Between-group differencea | |||||
---|---|---|---|---|---|---|---|
Baseline (n = 33) | Week 6 (n = 31) | Baseline (n = 31) | Week 6 (n = 29) | Diff. | 95% CI | Pvalue | |
Primary outcomes | |||||||
SPB, mmHg | 148.5 ± 12.3 | 130.5 ± 11.9 | 144.7 ± 14.4 | 143.8 ± 11.9 | -16.5 | -20.6 to 12.3 | < 0.001 |
HOMA index | 4.8 ± 7.2 | 3.6 ± 2.7 | 4.5 ± 3.8 | 4.1 ± 3.6 | -0.7 | -2.1 to 0.6 | 0.28 |
Secondary outcomes | |||||||
Glucose, mg/dl | 110.7 ± 29.4 | 98.5 ± 24.0 | 109.1 ± 34.4 | 107.3 ± 33.6 | -13.3 | -18.8 to -8.1 | < 0.001 |
HbA1c, % | 5.56 ± 0.61 | 5.36 ± 0.58 | 5.84 ± 1.24 | 5.72 ± 1.24 | -0.19 | -0.29 to -0.08 | < 0.001 |
Insulin, μU/ml | 15.4 ± 17.7 | 14.2 ± 8.9 | 16.7 ± 12.7 | 15.2 ± 11.6 | -1.2 | -5.4 to 3.0 | 0.580 |
Adiponectin, μg/ml | 9.15 ± 3.40 | 9.83 ± 5.00 | 8.75 ± 4.00 | 9.40 ± 4.40 | 0.24 | -0.90 to 1.39 | 0.68 |
hs-CRP, mg/dl | 0.32 ± 0.44 | 0.33 ± 0.39 | 0.30 ± 0.37 | 0.31 ± 0.38 | 0.01 | -0.05 to 0.07 | 0.80 |
DBP, mmHg | 93.2 ± 6.8 | 83.7 ± 5.7 | 90.8 ± 6.6 | 90.0 ± 8.6 | -8.2 | -10.7 to -5.7 | < 0.001 |
Heart rate, beats/min | 72.1 ± 8.2 | 70.0 ± 5.8 | 74.2 ± 9.5 | 76.2 ± 8.4 | -5.7 | -8.1 to -3.2) | < 0.001 |
Ferritin, ng/ml | 188.3 ± 212.4 | 104.6 ± 132.5 | 173.2 ± 132.9 | 149.4 ± 124.9* | -74.2 | 101.6 to -46.8 | < 0.001 |
Iron, ng/ml | 100.6 ± 34.2 | 75.8 ± 28.5 | 100.8 ± 26.2 | 102.8 ± 36.9* | -27.1 | -41.1 to -13.2 | < 0.001 |
Triglycerides, mg/dl | 154.0 ± 66.7 | 158.0 ± 64.7 | 204.6 ± 120.0 | 178. ± 70.7* | -2.9 | -31.4 to 25.6 | 0.84 |
Cholesterol, mg/dl | 208.4 ± 36.5 | 212.2 ± 38.6 | 211.0 ± 37.7 | 206.4 ± 36.4* | 3.1 | -6.7 to 12.8 | 0.54 |
HDL-C, mg/dl | 55.9 ± 15.0 | 58.9 ± 17.9 | 54.2 ± 16.5 | 55.0 ± 16.1* | 3.0 | -0.3 to 6.3 | 0.07 |
LDL-C, mg/dl | 131.2 ± 35.8 | 123.5 ± 35.9 | 130.7 ± 32.8 | 125.1 ± 29.1* | -4.9 | -11.8 to 2.0 | 0.16 |
LDL/HDL ratio | 2.48 ± 0.88 | 2.21 ± 0.80 | 2.56 ± 0.82 | 2.43 ± 0.82 | -0.23 | -0.38 to -0.08 | < 0.01 |